CN1423660A - 抗体 - Google Patents

抗体 Download PDF

Info

Publication number
CN1423660A
CN1423660A CN00818416A CN00818416A CN1423660A CN 1423660 A CN1423660 A CN 1423660A CN 00818416 A CN00818416 A CN 00818416A CN 00818416 A CN00818416 A CN 00818416A CN 1423660 A CN1423660 A CN 1423660A
Authority
CN
China
Prior art keywords
scfv
nucleotide sequence
dam
cells
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00818416A
Other languages
English (en)
Chinese (zh)
Inventor
A·金斯曼
S·M·金斯曼
C·R·贝兵顿
M·W·克罗尔
F·M·埃拉德
K·A·迈尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1999/003859 external-priority patent/WO2000029428A2/en
Priority claimed from GB0003527A external-priority patent/GB0003527D0/en
Priority claimed from GB0005071A external-priority patent/GB0005071D0/en
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Publication of CN1423660A publication Critical patent/CN1423660A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN00818416A 1999-11-18 2000-11-13 抗体 Pending CN1423660A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
PCT/GB1999/003859 WO2000029428A2 (en) 1998-11-18 1999-11-18 5t4 tumour-associated antigen for use in tumour immunotherapy
WOPCT/GB99/03859 1999-11-18
GB0003527.9 2000-02-15
GB0003527A GB0003527D0 (en) 2000-02-15 2000-02-15 Antibodies
GB0005071A GB0005071D0 (en) 2000-03-02 2000-03-02 Antibodies
GB0005071.6 2000-03-02

Publications (1)

Publication Number Publication Date
CN1423660A true CN1423660A (zh) 2003-06-11

Family

ID=27255534

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00818416A Pending CN1423660A (zh) 1999-11-18 2000-11-13 抗体

Country Status (7)

Country Link
US (3) US7074909B2 (https=)
EP (1) EP1242456B1 (https=)
JP (1) JP2003515323A (https=)
CN (1) CN1423660A (https=)
AU (1) AU1290001A (https=)
CA (1) CA2391925A1 (https=)
WO (1) WO2001036486A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749656A (zh) * 2016-11-11 2017-05-31 郑州师范学院 一种抗小鼠RCN3蛋白单克隆ScFv抗体及其淘选方法

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US6852703B1 (en) 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
ATE411342T1 (de) * 1999-11-18 2008-10-15 Oxford Biomedica Ltd Scfv antikörper gegen krankheiten-assoziierte moleküle
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
EP1347994A2 (en) 2000-11-13 2003-10-01 Oxford Biomedica (UK) Limited Canine and feline tumour-associated antigen 5t4
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
MXPA05001933A (es) * 2002-08-19 2005-04-28 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US7714119B2 (en) * 2004-07-13 2010-05-11 Biosante Pharmaceuticals, Inc. AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
SV2007002227A (es) * 2004-09-10 2007-03-20 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
JP5057967B2 (ja) 2005-03-31 2012-10-24 中外製薬株式会社 ｓｃ（Ｆｖ）２構造異性体
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
KR101367544B1 (ko) 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
CA2611726C (en) 2005-06-10 2017-07-11 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(fv)2
WO2006132352A1 (ja) * 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2を含有する医薬組成物
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
EP2076287A2 (en) 2006-10-12 2009-07-08 Wyeth Methods and compositions with reduced opalescence
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
KR100949791B1 (ko) * 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
US8642274B2 (en) * 2008-07-15 2014-02-04 Oxford Biomedica, Inc. Immunotherapeutic method
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
CA2846432A1 (en) * 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
KR101716555B1 (ko) 2012-01-24 2017-03-14 화이자 인코포레이티드 포유동물 대상체에서 5t4-양성 순환 종양 세포를 검출하는 방법 및 5t4-양성 암을 진단하는 방법
US20160304617A1 (en) 2013-06-17 2016-10-20 Asana Biosciences, Llc 5t4-targeted immunofusion molecule and methods
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
ES2754397T3 (es) * 2013-10-11 2020-04-17 Asana Biosciences Llc Conjugados de proteína-polímero-fármaco
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
WO2015133484A1 (ja) * 2014-03-04 2015-09-11 国立大学法人徳島大学 腎臓疾患に関するマーカー及びその利用
WO2016120331A1 (de) 2015-01-28 2016-08-04 Karl Sebastian Lang Agonistische anti-cd66cd66 antikörper für die antiviralen therapie
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
WO2019104289A1 (en) 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN111757757A (zh) 2017-12-21 2020-10-09 梅尔莎纳医疗公司 吡咯并苯并二氮呯抗体共轭物
SG11202008399QA (en) 2018-03-12 2020-09-29 Genmab As Antibodies
CN113365664A (zh) 2018-10-29 2021-09-07 梅尔莎纳医疗公司 具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
CN121311250A (zh) 2023-03-22 2026-01-09 信立泰生物医药公司 抗5t4抗原结合结构域、抗体-药物缀合物及其使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481051A (en) * 1969-02-06 1969-12-02 Paramount Packaging Corp Heating apparatus
US4009778A (en) * 1975-11-04 1977-03-01 The Kartridg Pak Co. Dual compartment package and method for making same
US4267768A (en) * 1976-09-20 1981-05-19 David M. Cieslak Process for fabricating a reclosable bag
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
EP0403559A1 (en) * 1988-03-04 1990-12-27 Cancer Research Campaign Technology Limited Improvements relating to antigens
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5060146A (en) 1988-04-08 1991-10-22 International Business Machines Corporation Multilingual indexing system for alphabetical lysorting by comparing character weights and ascii codes
CA2016897A1 (en) 1989-05-17 1990-11-17 John W. Wills Retrovirus-mediated secretion of recombinant products
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994026910A1 (en) * 1993-05-12 1994-11-24 Xoma Corporation Immunotoxins comprising gelonin and an antibody
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
US5582826A (en) * 1993-04-21 1996-12-10 Ajinomoto Co., Inc. Monoclonal antibodies which bind the gamma chain of human interleukin-2 receptor
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
DE69523857T2 (de) * 1994-09-16 2002-06-13 Merck Patent Gmbh Immunokonjugate
GB9423085D0 (en) 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
US5824762A (en) * 1994-11-28 1998-10-20 Dow Corning Toray Silicone Co., Ltd. Organopolysiloxane and method for the preparation of the same
WO1996030504A1 (en) 1995-03-24 1996-10-03 Genetic Therapy, Inc. Modified viral envelope polypeptide
FR2732348B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US5637462A (en) * 1995-04-19 1997-06-10 Incyte Pharmaceuticals, Inc. Cathepsin C homolog
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
CN1194009A (zh) * 1995-06-06 1998-09-23 人体基因组科学有限公司 结肠特异性基因及蛋白质
AU7719596A (en) 1995-11-07 1997-05-29 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
AU719513B2 (en) * 1996-05-04 2000-05-11 Astrazeneca Ab Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
JP4175678B2 (ja) * 1996-06-07 2008-11-05 武田薬品工業株式会社 新規ペプチド、その製造法および用途
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
US6348584B1 (en) * 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
US6852703B1 (en) * 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
JPH1156368A (ja) * 1997-08-27 1999-03-02 Nippon Seibutsu Kagaku Kenkyusho 猫トロンボポエチンの活性を有する因子
CN1357048A (zh) * 1998-03-06 2002-07-03 牛津生物医学（英国）有限公司 增强前体药物活化
EP1036091B2 (en) * 1998-11-18 2008-03-26 Oxford Biomedica (UK) Limited 5t4 tumour-associated antigen for use in tumour immunotherapy
ATE411342T1 (de) * 1999-11-18 2008-10-15 Oxford Biomedica Ltd Scfv antikörper gegen krankheiten-assoziierte moleküle
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749656A (zh) * 2016-11-11 2017-05-31 郑州师范学院 一种抗小鼠RCN3蛋白单克隆ScFv抗体及其淘选方法
CN106749656B (zh) * 2016-11-11 2018-04-13 郑州师范学院 一种抗小鼠RCN3蛋白单克隆ScFv抗体及其淘选方法

Also Published As

Publication number Publication date
US20100040539A1 (en) 2010-02-18
AU1290001A (en) 2001-05-30
EP1242456A2 (en) 2002-09-25
JP2003515323A (ja) 2003-05-07
EP1242456B1 (en) 2008-10-15
US20060014222A1 (en) 2006-01-19
WO2001036486A3 (en) 2002-05-10
WO2001036486A2 (en) 2001-05-25
US7514546B2 (en) 2009-04-07
US20070259400A1 (en) 2007-11-08
CA2391925A1 (en) 2001-05-25
US7074909B2 (en) 2006-07-11

Similar Documents

Publication Publication Date Title
CN1423660A (zh) 抗体
CN1224712C (zh) 载体
JP6559607B2 (ja) 新規なイムノコンジュゲート
CN1302103C (zh) CD19xCD3特异性多肽及其用途
HK1041210A1 (zh) 用於调节淋巴细胞活化的组合物及方法
CN1606453A (zh) Cripto阻断抗体及其用途
CN1268645C (zh) 含有抗－fc受体结合剂的治疗化合物
CN1341124A (zh) 抗cd3免疫毒素及其治疗用途
TW202110895A (zh) 一種抗ceacam5的單殖株抗體及其製備方法和用途
KR20230069955A (ko) 항-4-1bb-항-pd-l1 이중특이적 항체, 이의 약제학적 조성물 및 용도
CN1620468A (zh) 新的抗igf－ir抗体及其应用
KR20230042035A (ko) Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체
US20110052577A1 (en) Antibodies
JP2023539524A (ja) エンゲージャを含む薬物治療剤の開発及び応用
TW202448951A (zh) 經修飾之單域抗體
JP2022513050A (ja) ムチン－１６に対する抗体およびそれを使用する方法
WO2024131962A1 (zh) 新型抗gprc5d抗体
CN1230538C (zh) 与人ζ链胞外域特异性相互作用的免疫制剂
CN1572801A (zh) 具有抗肿瘤功能的双功能融合蛋白及其制备方法和应用
CN117693522A (zh) 具有改善的稳定性和表达的多肽复合物
HK1017693A (en) Therapeutic compounds comprised of anti-fc receptor antibodies
HK1090381A (en) Pharmaceutical composition comprising a bispecific antibody for epcam
HK1037674B (en) Cd19xcd3 specific polypeptides and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication